The latest advancement in pancreatic ductal adenocarcinoma therapy: A review article for the latest guidelines and novel therapies

Marwa Elsayed, Maen Abdelrahim

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presentation play a vital role in the high death rate from pancreatic cancer. In addition to this, the low mutation burden in pancreatic cancer, low immunological profile, dense tumorigenesis stroma, and decreased tumor sensitivity to cytotoxic drugs contribute to the low survival rates in PDAC patients. Despite breakthroughs in chemotherapeutic and immunotherapeutic drugs, pancreatic cancer remains one of the solid tumors that exhibit meager curative rates. Therefore, researchers must dedicate more effort to understanding the pathology and immunological behavior of PDAC, in addition to properly utilizing more advanced screening modalities and new therapeutic agents. In our review, we focus mainly on the latest updates from clinical guidelines and novel therapies that have been recently investigated or are under investigation for PDAC. We used PubMed as a search tool for finding original research articles addressing the latest developments in diagnosing and treating PDAC. Additionally, we also used the clinical trials published on clinicaltrialsgov as sources for our data.

Original languageEnglish (US)
Article number389
JournalBiomedicines
Volume9
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • Pancreatic cancer
  • Pancreatic cancer novel therapy
  • Pancreatic cancer treatment
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'The latest advancement in pancreatic ductal adenocarcinoma therapy: A review article for the latest guidelines and novel therapies'. Together they form a unique fingerprint.

Cite this